Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540320 | 0.90 | MTNR1A (0.43) | MTNR1ANQO2TDP1NPC1RAB9A | |
| SCHEMBL5538684 | 0.88 | MTNR1A (0.42) | MTNR1ANQO2TDP1NPC1RAB9A | |
| SCHEMBL5543510 | 0.87 | SLC16A3 (0.41) | MTNR1ANQO2TDP1NPC1RAB9A | |
| SCHEMBL5542952 | 0.87 | SLC16A3 (0.41) | MTNR1ANQO2TDP1NPC1RAB9A | |
| SCHEMBL27554620 | 0.85 | NPC1 (0.38) | MTNR1ANQO2NPC1RAB9A | |
| SCHEMBL4514414 | 0.82 | CYP1A2 (0.44) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL29853 | 0.81 | NPC1 (0.54) | TDP1NPC1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL27655056 | 0.79 | TRPM4 (0.36) | TDP1NPC1RAB9ACYP1A2 | |
| SCHEMBL586305 | 0.79 | CYP1A2 (0.52) | MTNR1ANQO2TDP1CYP1A2CYP2C19 | |
| SCHEMBL14724998 | 0.79 | HTR2A (0.60) | MTNR1ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| CN-1886124-A | Method for inhibiting production of remnant lipoproteins | JAPAN TOBACCO INC (JP) | 2006-12-27 | — | — | CN | claimed |
| CN-1635911-A | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | PFIZER PROD INC (US) | 2005-07-06 | — | — | CN | claimed |
| US-20240156792-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-05-16 | — | — | US | disclosed |
| WO-2024075815-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2024-04-11 | — | — | WO | disclosed |
| US-11918562-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-03-05 | — | — | US | disclosed |
| US-20220016090-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-20 | — | — | US | disclosed |
| US-11166943-B2 | Combination therapy using azabicyclo compound for cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-09 | — | — | US | disclosed |
| WO-2021025065-A1 | COMBINATION THERAPY FOR CANCER USING AZABICYCLIC COMPOUND AND POLY(ADENOSINE 5'-DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITOR | 大鵬薬品工業株式会社 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021024393-A1 | CANCER COMBINATION THERAPY USING AZABICYCLIC COMPOUND AND POLYADENOSINE-5'-DIPHOSPHATE RIBOSE POLYMERASE INHIBITOR | 大鵬薬品工業株式会社 | 2021-02-11 | — | — | WO | disclosed |
| US-5432195-A | Anticholesterol | NIPPON SHINYAKU COMPANY LIMITED (JP) | 1995-07-11 | — | — | US | disclosed |
| EP-0601181-A1 | BENZOFURAN DERIVATIVE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4276305-A | INSECTICIDES, MITICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-06-30 | — | — | US | disclosed |
| US-4057550-A | 14,15-DIHYDRO-14-CYANO-EBURNAMENINES, VASODILATION | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-11-08 | — | — | US | disclosed |
| US-4054571-A | Nitrogen-containing polycyclic compounds and a process for the preparation thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156792-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 4438/4885NQO2 1245/4885TDP1 2033/4885 |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | MTNR1A 2011/4885NQO2 194/4885TDP1 3778/4885 |
| US-11918562-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 4438/4885NQO2 1245/4885TDP1 2033/4885 |
| US-20220016090-A1 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 4438/4885NQO2 1245/4885TDP1 2033/4885 |
| US-11166943-B2 | Combination therapy using azabicyclo compound for cancer | HSP90AB1, HSP90AA1, HSP90AB2P | MTNR1A 4438/4885NQO2 1245/4885TDP1 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.